Given these outcomes, the use of both PD-1 inhibitor and β-catenin siRNA can exert a synergistic effect to promote CD8+ T cells’ infiltration into the HCC TME [93]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.